|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc
Netw. 10:1236–1271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bejjani BA and Shaffer LG: Clinical
utility of contemporary molecular cytogenetics. Annu Rev Genomics
Hum Genet. 9:71–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang C, Li HR, Fan JB, Wang-Rodriguez J,
Downs T, Fu XD and Zhang MQ: Profiling alternatively spliced mRNA
isoforms for prostate cancer classification. BMC Bioinformatics.
7:2022006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu M, Deng X, Joshi T, Xu D, Stacey G and
Cheng J: Reconstructing differentially co-expressed gene modules
and regulatory networks of soybean cells. BMC Genomics. 13:4372012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Denoix PF: Enquete permanent dans les
centres anticancereaux. Bull Inst Nat Hyg. 1:70–75. 1946.(In
French).
|
|
8
|
Meister M, Belousov A, Xu EC, et al:
Intra-tumor heterogeneity of gene expression profiles in early
stage non-small cell lung cancer. J Bioinf Res Stud. 1:12014.
|
|
9
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Phipson B, Lee S, Majewski IJ, Alexander
WS and Smyth GK: Robust hyperparameter estimation protects against
hypervariable genes and improves power to detect differential
expression. Ann Appl Stat. 10:946–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martucci D, Masseroli M and Pinciroli F:
Gene ontology application to genomic functional annotation,
statistical analysis and knowledge mining. Stud Health Technol
Inform. 102:108–131. 2004.PubMed/NCBI
|
|
12
|
Kanehisa M: The KEGG database. Novartis
Found Symp. 247:91–103, 119-128, 244–152. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Langley SR, Dwyer J, Drozdov I, Yin X and
Mayr M: Proteomics: From single molecules to biological pathways.
Cardiovasc Res. 97:612–622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Burrell RA, McGranahan N, Bartek J and
Swanton C: The causes and consequences of genetic heterogeneity in
cancer evolution. Nature. 501:338–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu M, Fan R, Liu X, Cheng F and Wang J:
Pathways and networks-based analysis of candidate genes associated
with nicotine addiction. PLoS One. 10:e01274382015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szasz AM, Lanczky A, Nagy A, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gridelli C, Rossi A, Carbone DP, Guarize
J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R:
Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
An Q, Han C, Zhou Y, Li F, Li D, Zhang X,
Yu Z, Duan Z and Kan Q: Matrine induces cell cycle arrest and
apoptosis with recovery of the expression of miR-126 in the A549
non-small cell lung cancer cell line. Mol Med Rep. 14:4042–4048.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jung CK, Jung JH, Lee KY, Kang CS, Kim M,
Ko YH and Oh CS: Centrosome abnormalities in non-small cell lung
cancer: correlations with DNA aneuploidy and expression of cell
cycle regulatory proteins. Pathol Res Pract. 203:839–847. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao PC, Begum S, Jahromi MA, Jahromi ZH,
Sriram S and Sahai M: Cytotoxicity of withasteroids: Withametelin
induces cell cycle arrest at G2/M phase and mitochondria-mediated
apoptosis in non-small cell lung cancer A549 cells. Tumour Biol.
37:12579–12587. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Xu J, Zhao C, Zhao L and Feng B:
Antiproliferative, cell-cycle dysregulation effects of novel
asiatic acid derivatives on human non-small cell lung cancer cells.
Chem Pharm Bull (Tokyo). 61:1015–1023. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haura EB: Is repetitive wounding and bone
marrow-derived stem cell mediated-repair an etiology of lung cancer
development and dissemination? Med Hypotheses. 67:951–956. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hai J, Sakashita S, Allo G, Ludkovski O,
Ng C, Shepherd FA and Tsao MS: Inhibiting MDM2-p53 interaction
suppresses tumor growth in patient-derived non-small cell lung
cancer xenograft models. J Thorac Oncol. 10:1172–1180. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
In JK, Kim JK, Oh JS and Seo DW:
5-Caffeoylquinic acid inhibits invasion of non-small cell lung
cancer cells through the inactivation of p70S6K and Akt activity:
Involvement of p53 in differential regulation of signaling
pathways. Int J Oncol. 48:1907–1912. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fukushi S, Yoshino H, Yoshizawa A and
Kashiwakura I: p53-independent structure-activity relationships of
3-ring mesogenic compounds' activity as cytotoxic effects against
human non-small cell lung cancer lines. BMC Cancer. 16:5212016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Albelda SM and Buck CA: Integrins and
other cell adhesion molecules. FASEB J. 4:2868–2880. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hall CL and Turley EA: Hyaluronan: RHAMM
mediated cell locomotion and signaling in tumorigenesis. J
Neurooncol. 26:221–229. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu
J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its
derivatives can significantly inhibit lung tumorigenesis and tumor
metastasis through Wnt/β-catenin signaling. Oncotarget.
7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ashton TM, Fokas E, Kunz-Schughart LA,
Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM,
Hammond EM, et al: The anti-malarial atovaquone increases
radiosensitivity by alleviating tumour hypoxia. Nature Commun.
7:123082016. View Article : Google Scholar
|
|
33
|
Castedo M, Perfettini JL, Roumier T and
Kroemer G: Cyclin-dependent kinase-1: Linking apoptosis to cell
cycle and mitotic catastrophe. Cell Death Differ. 9:1287–1293.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi YX, Zhu T, Zou T, Zhuo W, Chen YX,
Huang MS, Zheng W, Wang CJ, Li X, Mao XY, et al: Prognostic and
predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
Oncotarget. 7:85235–85243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Danilov AV, Hu S, Orr B, Godek K,
Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA,
et al: Dinaciclib induces anaphase catastrophe in lung cancer cells
via inhibition of cyclin-dependent kinases 1 and 2. Mol Cancer
Ther. 15:2758–2766. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lane HA and Nigg EA: Antibody
microinjection reveals an essential role for human polo-like kinase
1 (Plk1) in the functional maturation of mitotic centrosomes. J
Cell Biol. 135:1701–1713. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiao D, Yue M, Su H, Ren P, Jiang J, Li F,
Hu Y, Du H, Liu H and Qing G: Polo-like kinase-1 regulates Myc
stabilization and activates a feedforward circuit promoting tumor
cell survival. Mol Cell. 64:493–506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goldenson B and Crispino JD: The aurora
kinases in cell cycle and leukemia. Oncogene. 34:537–545. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Woo JK, Kang JH, Shin D, Park SH, Kang K,
Nho CW, Seong JK, Lee SJ and Oh SH: Daurinol enhances the efficacy
of radiotherapy in lung cancer via suppression of aurora kinase a/b
expression. Mol Cancer Ther. 14:1693–1704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T
and Baum LG: A novel mammalian protein, p55CDC, present in dividing
cells is associated with protein kinase activity and has homology
to the Saccharomyces cerevisiae cell division cycle proteins Cdc20
and Cdc4. Mol Cell Biol. 14:3350–3363. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie Q, Wu Q, Mack SC, Yang K, Kim L,
Hubert CG, Flavahan WA, Chu C, Bao S and Rich JN: CDC20 maintains
tumor initiating cells. Oncotarget. 6:13241–13254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Choi JW, Kim Y, Lee JH and Kim YS: High
expression of spindle assembly checkpoint proteins CDC20 and MAD2
is associated with poor prognosis in urothelial bladder cancer.
Virchows Arch. 463:681–687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang DZ, Ma Y, Ji B, Liu Y, Hwu P,
Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is
associated with pancreatic ductal adenocarcinoma differentiation
and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kato T, Daigo Y, Aragaki M, Ishikawa K,
Sato M and Kaji M: Overexpression of CDC20 predicts poor prognosis
in primary non-small cell lung cancer patients. J Surg Oncol.
106:423–430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han X, Liu M, Wang S, Lv G, Ma L, Zeng C
and Shi Y: An integrative analysis of the putative
gefitinib-resistance related genes in a lung cancer cell line model
system. Curr Cancer Drug Targets. 15:423–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Davenport JW, Fernandes ER, Harris LD,
Neale GA and Goorha R: The mouse mitotic checkpoint gene bub1b, a
novel bub1 family member, is expressed in a cell cycle-dependent
manner. Genomics. 55:113–117. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen H, Lee J, Kljavin NM, Haley B, Daemen
A, Johnson L and Liang Y: Requirement for BUB1B/BUBR1 in tumor
progression of lung adenocarcinoma. Genes Cancer. 6:106–118.
2015.PubMed/NCBI
|
|
48
|
Moldovan GL, Pfander B and Jentsch S:
PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bodduluru LN, Kasala ER, Madhana RM, Barua
CC, Hussain MI, Haloi P and Borah P: Naringenin ameliorates
inflammation and cell proliferation in benzo(a)pyrene induced
pulmonary carcinogenesis by modulating CYP1A1, NFkappaB and PCNA
expression. Int Immunopharmacol. 30:102–110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chueh AC, Wong LH, Wong N and Choo KH:
Variable and hierarchical size distribution of
L1-retroelement-enriched CENP-A clusters within a functional human
neocentromere. Hum Mol Genet. 14:85–93. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Folco HD, Pidoux AL, Urano T and Allshire
RC: Heterochromatin and RNAi are required to establish CENP-A
chromatin at centromeres. Science. 319:94–97. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Toh SH, Prathipati P, Motakis E, Kwoh CK,
Yenamandra SP and Kuznetsov VA: A robust tool for discriminative
analysis and feature selection in paired samples impacts the
identification of the genes essential for reprogramming lung tissue
to adenocarcinoma. BMC Genomics. 12(Suppl 3): S242011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xu L, Deng HX, Yang Y, Xia JH, Hung WY and
Siddque T: Assignment of mitotic arrest deficient protein 2
(MAD2L1) to human chromosome band 5q23.3 by in situ hybridization.
Cytogenet Cell Genet. 78:63–64. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Guo Y, Zhang X, Yang M, Miao X, Shi Y, Yao
J, Tan W, Sun T, Zhao D, Yu D, et al: Functional evaluation of
missense variations in the human MAD1L1 and MAD2L1 genes and their
impact on susceptibility to lung cancer. J Med Genet. 47:616–622.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zlotnik A, Burkhardt AM and Homey B:
Homeostatic chemokine receptors and organ-specific metastasis. Nat
Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zlotnik A and Yoshie O: The chemokine
superfamily revisited. Immunity. 36:705–716. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wald O, Shapira OM and Izhar U:
CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic
roles and therapeutic potential. Theranostics. 3:26–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Suzuki M, Mohamed S, Nakajima T, Kubo R,
Tian L, Fujiwara T, Suzuki H, Nagato K, Chiyo M, Motohashi S, et
al: Aberrant methylation of CXCL12 in non-small cell lung cancer is
associated with an unfavorable prognosis. Int J Oncol. 33:113–119.
2008.PubMed/NCBI
|
|
59
|
Hartmann TN, Burger JA, Glodek A, Fujii N
and Burger M: CXCR4 chemokine receptor and integrin signaling
co-operate in mediating adhesion and chemoresistance in small cell
lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ebina M, Steinberg SM, Mulshine JL and
Linnoila RI: Relationship of p53 overexpression and up-regulation
of proliferating cell nuclear antigen with the clinical course of
non-small cell lung cancer. Cancer Res. 54:2496–2503.
1994.PubMed/NCBI
|
|
61
|
Matturri L, Lavezzi AM, Grignani F,
Salomoni G and Roviaro GC: The prognostic value of cell
proliferation in non-small cell lung cancer assessed with tritiated
thymidine and anti-PCNA antibodies. Eur J Cancer. 30A:1397–1398.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Alemany Monraval P, Martorell Cebollada M,
Salvador Villalba I and Martínez Leandro E: Study of the expression
of proliferating cell nuclear antigen and p185 in non-small cell
lung carcinoma. Arch Bronconeumol. 32:(In Spanish):. 165–169. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Castellano VM, Sotelo T, Ballestin C,
Lopez-Encuentra A and Varela G: Analysis of proliferating cell
nuclear antigen (PCNA) expression in 24 cases of primary non-small
cell pulmonary carcinomas and correlation with survival. Arch
Bronconeumol. 32:(In Spanish):. 127–131. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Guo X, Li D, Wu Y, Chen Y, Zhou X, Wang X,
Huang X, Li X, Yang H and Xing J: Genetic variants in genes of
tricarboxylic acid cycle key enzymes are associated with prognosis
of patients with non-small cell lung cancer. Lung Cancer.
87:162–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Di JZ, Peng JY and Wang ZG: Prevalence,
clinicopathological characteristics, treatment, and prognosis of
intestinal metastasis of primary lung cancer: A comprehensive
review. Surg Oncol. 23:72–80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
North CM and Christiani DC: Women and lung
cancer: What is new? Semin Thorac Cardiovasc Surg. 25:87–94. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lin J and Beer DG: Molecular predictors of
prognosis in lung cancer. Ann Surg Oncol. 19:669–676. 2012.
View Article : Google Scholar : PubMed/NCBI
|
